The Nigerian Investor
← All researchFidson Healthcare Plc (FIDSON) · Pharmaceuticals · 9M 2026

Fidson 9M 2026: Profit Up 47%, but FX Did Most of the Heavy Lifting

The verdict

Fidson remains Nigeria's largest listed drugmaker, the first to pass N100bn of annual revenue (N119.06bn in FY2025), and it is still growing about 21% on that base. Q3 was its best quarter: revenue rose 25.3% and PAT more than doubled to N4.02bn. But its earnings quality is weaker than the headline suggests, cash collection and debt management lagged the growth story, and at about 18.7x trailing earnings and 4.2x book the shares already price in sustained growth. A hold-quality franchise, not a bargain.

Key numbers (9M 2026 vs 9M 2025, N'bn)

Item

9M 2026

9M 2025

Change

Revenue

112.61

93.08

+21.0%

Gross profit

48.94

—

+28.1%

Gross margin

43.45%

41.06%

+2.4ppt

Admin expenses

16.42

—

+65.8%

Selling & distribution

11.51

—

+50.2%

Operating profit

21.24

—

+25.4%

Net FX loss

0.104

4.16

−97%

Finance costs

3.73

5.14

−27.4%

PBT

17.79

11.90

+49.5%

Tax (ETR ~34%)

6.05

—

+54.0%

PAT

11.74

7.97

+47.2%

Basic EPS

N3.91

—

+12.7%

Q3 revenue / PAT

38.13 / 4.02

—

+25.3% / +106%

Reported figures from Fidson's NGX filing as reported by Nairametrics (28 Oct 2026) and BusinessDay. "—" means the prior-year figure was not given in those sources.

What drove the results

Revenue mix: ethical products N69.19bn (+13.2%, about 61% of revenue); OTC N35.05bn (+26.0%); consumer healthcare N6.39bn (+69.8%); exports up to N1.98bn from N364.6m, though Nigeria is still about 98% of sales.

Margins and costs: gross margin widened about 2.4 points with the stable naira, but admin (+66%) and selling costs (+50%) grew far faster than revenue, so operating margin rose only to 18.9%. Below EBIT, net FX losses fell by about N4.06bn, roughly 69% of the N5.89bn rise in PBT. Finance costs fell 27%, mostly from lower commercial-paper interest. In short: the operating business grew about 25%. The extra 22 points of PBT growth were mostly macro.

Forensic flags

  1. Receivables explosion. Trade and other receivables rose about 165% to N29.32bn against 21% revenue growth, about 71 receivable days. Watch for impairment charges in the FY audited accounts.

  2. Debt rose despite the rights issue. Fidson raised about N21bn through a rights issue at N35, and the prospectus earmarked N9.5bn for debt repayment. Yet borrowings rose about 70% to N23.85bn: it repaid N20.29bn but drew N30.16bn.

  3. Operating cash flow flattered by working capital. OCF of N32.62bn looks like 2.8x PAT, but it was supported by a N23.72bn rise in payables and N17.53bn released from prepayments. Stretching suppliers is a one-off, not recurring cash.

  4. Inventory build. Inventory rose 39% to N36.96bn, about 158 inventory days.

  5. Dilution. EPS grew only 12.7% against 47% PAT growth because of the enlarged share base.

Valuation (TNI Research calculations)

  • Price N85.00 (30 Sep 2026); market cap about N255bn.

  • TTM PAT about N13.65bn; TTM EPS about N4.55 on 3.0bn shares; P/E about 18.7x.

  • Equity N60.01bn; P/B about 4.2x.

  • FY2025 dividend N1.50, a yield of about 1.8%.

  • Net debt about N12.9bn (about 22% of equity); interest cover about 5.7x.

What to watch in Q4 / FY 2026

  • Whether receivables fall in Q4, and impairment provisioning.

  • Whether gross borrowings fall now that rights proceeds are in.

  • Whether admin cost growth slows toward revenue growth.

  • Whether FX losses stay near zero: the 2026 tailwind does not repeat in 2027.

  • The FY dividend, now spread over 25% more shares.

Sources

Sources: Fidson 9M 2026 NGX filing via Nairametrics and BusinessDay. This is analysis for education, not investment advice.

TNI Research publishes independent analysis for education. It is not investment advice. Do your own research or consult a licensed adviser before investing.